VivoSeq
Cardiovascular

Dilated Cardiomyopathy

30

Pipeline Programs↗

13

Active Trials↗

15

Companies Involved↗

Dilated Cardiomyopathy is an emerging landscape with 30 programs across 15 companies. The most active players are Bristol-Myers Squibb, Eastern Cooperative Oncology Group, Menarini International Operations Luxembourg SA. 6 therapies are approved with 5 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

54/100

Pipeline Velocity

19/100

Mech. Concentration

15/100

Completion Rate

75/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 2E

Eastern Cooperative Oncology Group

1 program

Phase 2M

Menarini International Operations Luxembourg SA

1 program

Phase 2Sanofi logo

Sanofi

1 program

Phase 2T

Translational Biosciences

1 program

Phase 2Eli Lilly logo

Eli Lilly

2 programs

Phase 2

Pipeline

Programs by Phase

Preclinical5

Allopurinol

Alnylam Pharmaceuticals

Rosiglitazone

Alnylam Pharmaceuticals

Nesiritide

Scios, Inc.

Other

AstraZeneca

Rosiglitazone Therapy

Stanford University

Phase 14

FAP Immunosuppressive CAR-DC

Second Affiliated Hospital, School of Medicine, Zhejiang University

Allogeneic Cardiosphere-Derived Cells (cdcs)

Capricor Inc.

AZD4063

AstraZeneca

JV001

Shanghai East Hospital

Phase 210

Filgrastim

Eastern Cooperative Oncology Group

Ranolazine

Menarini International Operations Luxembourg SA

Simvastatin

Organon and Co

Dobutamine

Eli Lilly

Granulocyte Colony-Stimulating Factor

Sanofi

Phase 35

Candesartan

AstraZeneca

Perindopril

Institut de Recherches Internationales Servier

Stem Cell Therapy

University Hospital, Basel, Switzerland

ARRY-371797 (PF-07265803)

Pfizer

Enalapril Orodispersible Minitablet

Ethicare GmbH

Approved6

Coenzyme Q10

Mclean Hospital

Sirolimus

Prism Pharmaceuticals

Valsartan

Novartis

Rosuvastatin

AstraZeneca

Metoprolol

Bp Consulting, Inc

Analysis

Modality Breakdown

82%

Small molecule

32 of 39 classified programs — the dominant modality here.

18%ALL OTHERSCell therapy513%Protein / enzyme13%Peptide13%

Small molecule leads; the ring shows all 39 classified programs, each share of the total. Modality classified for 96% of 47 pipeline programs.

Analysis

Trial Status

42

clinical trials

Completed18 · 43%
Recruiting11 · 26%
Terminated5 · 12%
Unknown status5 · 12%
Active, not recruiting2 · 5%
Withdrawn1 · 2%

Clinical Trials

Trial Activity

42 trials

Therapy to Maintain Remission in Dilated Cardiomyopathy
Recruiting·IImperial College London·N/A·NCT06091475·50 enrolled
Early Treatment With Candesartan vs Placebo in Genetic Carriers of Dilated Cardiomyopathy (EARLY-GENE Trial)
Recruiting·—·Phase 3·NCT05321875·320 enrolled
The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus
Recruiting·TTongji Hospital·Phase 4·NCT06236022·276 enrolled
Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy
Recruiting·—·Phase 2·NCT04476901·136 enrolled
Bromocriptine in Dilated Cardiomyopathy Among Women of Reproductive Age
Recruiting·JJimma University·Phase 3·NCT06250257·112 enrolled
A Study of AZD4063 in PLN R14del Dilated Cardiomyopathy
Recruiting·AstraZeneca logoAstraZeneca·Phase 1·NCT07241104·31 enrolled
Registry of Cell Therapy in Non-Ischemic Dilated Cardiomyopathy
Recruiting·UUniversity Medical Centre Ljubljana·N/A·NCT02445534·250 enrolled
ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy
Recruiting·AstraZeneca logoAstraZeneca·Phase 1/2·NCT07218887·6 enrolled
A Phase 1/2, First-in-Human, Open-Label, Multicenter, Single-Dose Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of NVC-001, a Novel Adeno-Associated Virus (Serotype 9) Vector Expressing a Dominant Negative SUN1 Transgene, in Patients With LMNA-Related Dilated Cardiomyopathy (SUNBEAM-LMNA)
Recruiting·NNuevocor Pte. Ltd.·Preclinical·NCT07606274·21 enrolled
A Phase 2b/3, Adaptive, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
Recruiting·KKardigan, Inc.·Preclinical·NCT07210723·332 enrolled
A Phase 1 Open-Label Study of the Safety of Intravenous Allogeneic Neonatal Mesenchymal Cells (nMSCs) in Young Adult (1A) and Pediatric (1B) Patients With Dilated Cardiomyopathy (DCM)
Recruiting·EEmory University·Phase 1·NCT06464588·36 enrolled
Safety and Efficacy of FAP iCDC in End-stage Dilated Cardiomyopathy
Active, not recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1·NCT06902896·9 enrolled
Myocardial Telomere Recapping Study for Dilated Cardiomyopathy
Active, not recruiting·SShanghai East Hospital·Phase 1·NCT05837143·12 enrolled
Simvastatin Therapy in Patients With Dilated Cardiomyopathy.
Completed·NNational Taiwan University Hospital·Phase 2·NCT03775070·8 enrolled
A Pilot Trial of Ranolazine to Treat Patients With Dilated Cardiomyopathy
Completed·UUniversity Medical Centre Ljubljana·Phase 2·NCT02133911·10 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)